Research Reports | Market Assessment
November 2016

Multiple Sclerosis | Unmet Need | Chronic Progressive Multiple Sclerosis | US/EU | 2016

No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current treatment relies heavily on off-label use of products approved for the treatment of relapsing forms of MS, or anti-inflammatory agents that are not approved at all for MS. This Unmet Need content provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need in CP-MS. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports